| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H19N3O3 |
| Molecular Weight | 337.3725 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1CC2=C(C=C3OCOC3=C2)C(=NN1C(C)=O)C4=CC=C(N)C=C4
InChI
InChIKey=JACAAXNEHGBPOQ-LLVKDONJSA-N
InChI=1S/C19H19N3O3/c1-11-7-14-8-17-18(25-10-24-17)9-16(14)19(21-22(11)12(2)23)13-3-5-15(20)6-4-13/h3-6,8-9,11H,7,10,20H2,1-2H3/t11-/m1/s1
Talampanel (TLP) was developed as a noncompetitive (allosteric) antagonist of the AMPA receptor. Talampanel does not act directly on the AMPA receptor, but at an allosteric site referred to as the GYKI receptor. Talampanel is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy, Parkinson disease, amyotrophic lateral sclerosis, dyskinesias, glioblastoma, multiple sclerosis. It is a type of AMPA receptor antagonist. Dizziness has been the most commonly reported adverse event, with some sedation and ataxia, drowsiness and headaches reported at higher doses.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
25 or 50mg Talampanel 3 times per day (during 52 weeks).
Route of Administration:
Oral
ACTIVE MOIETY
